AMT-676 / Multitude Therap - LARVOL DELTA

A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT06400485 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P1 data • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor • CDH17

AMT-676 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Multitude Therapeutics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

AMT-676 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Multitude Therapeutics Inc.

Metastases • New P1 trial • Oncology • Solid Tumor